NCT02993523 · OUTCOME

Complete Remission (CR) Rate

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy · Source last updated 2026-06-11

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Measured up to 2 years after the last participant is randomized

What was measured

The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-01
denom Units Selected: Participants
description: The percentage of participants with complete remission (CR) will be calculated based on the modified IWG criteria for AML.
reporting Status: NOT_POSTED
time Frame: Measured up to 2 years after the last participant is randomized
title: Complete Remission (CR) Rate
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice